Evidence map›Paper›PMID 40035507›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

A Tetrazine-Based Synthesis for Accessing Underutilized Aza-Indole Analogues.

Evan Savelson, Katarina A Selewski, Jetze J Tepe

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Tetrazine-Based Synthesis for Accessing Underutilized Aza-Indole Analogues.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Evan SavelsonDepartment of Chemistry, University of Virginia, 409 McCormick Rd, Charlottesville, VA, 22904, USA.ORCID https://orcid.org/0000-0001-8963-3071
Katarina A SelewskiDepartment of Chemistry, University of Virginia, 409 McCormick Rd, Charlottesville, VA, 22904, USA.ORCID https://orcid.org/0009-0000-9704-7849
Jetze J TepeDepartment of Chemistry, University of Virginia, 409 McCormick Rd, Charlottesville, VA, 22904, USA.ORCID https://orcid.org/0000-0001-5467-5589

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Development of cellular HTS for 20S proteasome enhancersR61NS111347 · NINDS · MICHIGAN STATE UNIVERSITY · PI LISABETH, ERIKA MATHES, NEUBIG, RICHARD R · 2020 to 2021
$699k
Development of Cellular HTS for 20S Proteasome EnhancersR33NS111347 · NINDS · MICHIGAN STATE UNIVERSITY · PI LISABETH, ERIKA MATHES, NEUBIG, RICHARD R · 2022 to 2022
$384k
NIH HHS P30CA044579NINDS NIH HHS NS111347NINDS NIH HHS R33 NS111347NINDS NIH HHS R61 NS111347
6 · The paper itself

Abstract

Aza-indole functionalities fill an important role in drug discovery. While indoles are considered privileged scaffolds, aza-indoles allow for better pharmacological properties and on-target activities. Synthetic approaches to access aza-indoles are limited, with pyrazolopyridazines being some of the scarcest aza-indoles. To provide access to these underutilized cores, a synthetic approach utilizing a reaction cascade between a protected propargylhydrazine and dichlorotetrazine has been developed. In addition, a variety of methods were developed to access each position on the core for late-stage functionalization. This method offers an expedited synthetic route to a rare aza-indole scaffold with superior physiochemical properties when compared to indole analogues.

Indexed as

Aza CompoundsIndolesMolecular StructureAza CompoundsIndolesAza-indolesCycloadditionHeterocyclesPyrazolopyridazinesTetrazine

Identifiers

PMID40035507
PMCPMC12057616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.